Cited by 34Protein purification and stabilityBacterial Genetics and BiotechnologyMonoclonal and Polyclonal Antibodies Research

Development of a high yielding E. coli periplasmic expression system for the production of humanized Fab' fragments

Ellis, Mark, Patel, Pareshkumar, Edon, Marjory, Ramage, Walter, Dickinson, Robert., Humphreys, David P.·2017·Biotechnology Progress

Abstract

Humanized Fab' fragments may be produced in the periplasm of Escherichia coli but can be subject to degradation by host cell proteases. In order to increase Fab' yield and reduce proteolysis we developed periplasmic protease deficient strains of E. coli. These strains lacked the protease activity of Tsp, protease III and DegP. High cell density fermentations indicated Tsp deficient strains increased productivity two fold but this increase was accompanied by premature cell lysis soon after the induction of Fab' expression. To overcome the reduction in cell viability we introduced suppressor mutations into the spr gene. The mutations partially restored the wild type phenotype of the cells. Furthermore, we coexpressed a range of periplasmic chaperone proteins with the Fab', DsbC had the most significant impact, increasing humanized Fab' production during high cell density fermentation. When DsbC coexpression was combined with a Tsp deficient spr strain we observed an increase in yield and essentially restored "wild type" cell viability. We achieved a final periplasmic yield of over 2.4g/L (final cell density OD 600 105), 40 h post Fab' induction with minimal cell lysis.The data suggests that proteolysis, periplasm integrity, protein folding and disulphide bond formation are all potential limiting steps in the production of Fab' fragments in the periplasm of E. coli. In this body of work, we have addressed these limiting steps by utilizing stabilized protease deficient strains an…

Integrity signals

Registry

Crossref · 10.1002/btpr.2393

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ellis developed a novel approach based on coexpression of Fab fragments with DsbC in engineered E. coli Tsp spr strains, achieving a yield of periplasmic Fab over 2.4 g/L in fermentation scale after 40 h post-induction.

    “Similarly, Ellis and coworkers developed a novel approach based on the coexpression of Fab fragments with DsbC in ad hoc engineered E. coli strain (Tsp spr strains) achieving a very high yield of periplasmic Fab approaching over 2.4 g/L in fermentation scale after 40 h post-induction [56].”
  • The synergistic effect of DsbA/DsbC has been successfully assessed as an effective way to improve the soluble expression of Fabs and scFvs in the E. coli periplasmic space.

    “The synergistic effect of DsbA/DsbC has been next successfully assessed as an effective way to improve the soluble expression of Fabs [56,88] and scFvs [170] in the E. coli periplasmic space.”
  • When the same Fab was coexpressed with DsbC in fermentation scale using an engineered E. coli strain deficient in Tsp and SRP, an optimal recovery of 2.4 g/L was reached.

    “When the same Fab was coexpressed with DsbC in fermentation scale using the ad hoc genetically modified E. coli strain deficient in the Tail specific protease (Tsp) and SRP, an optimal recovery of 2.4 g/L was reached [56].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ellis, M., Patel, P., Edon, M., Ramage, W., Dickinson, R., & Humphreys, D. P.
Affiliations
  • UCB Pharma (United Kingdom) (GB)
  • Lonza (United Kingdom) (GB)
  • Novasep, 5 chemin du Pilon, St Maurice de Beynost Miribel 01708 France
  • National Institute for Biological Standards and Control (GB)
  • CSL (Australia) (AU)
Corresponding author
Ellis, Mark
Venue
Biotechnology Progress
Publisher
Wiley
Published
2016-11-17
Volume
33
Issue
1
Pages
212-220
ISSN
  • 1520-6033 (ISSN-L)
  • 8756-7938
OpenAlex
W2552158877
Cited by
34
References
2
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 8 · 2020: 6 · 2019: 4 · 2018: 2 · 2017: 1
FWCI
1.21
Type
journal article
Language
en
Open access
closed
Locations
  • Biotechnology Progress (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Keywords
periplasmic expression, Escherichia coli, protease-deficient strain, DsbC, periplasmic chaperone, disulfide bond formation, protein folding, proteolysis, cell lysis, high cell density fermentation, monoclonal antibody production
MeSH terms
Escherichia coli, Fermentation, Humans, Immunoglobulin Fab Fragments, Peptide Hydrolases, Protein Engineering, Protein Folding, Periplasm, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review